A novel mutant, ApoA-I Nichinan (Glu235→0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1447-1455

  Han, Hua ^a   Sasaki, Jun ^a   Matsunaga, Akira ^a   Hakamata, Hideki ^c   Huang, Wei ^a   Ageta, Masato ^b   Taguchi, Toshifumi ^b   Koga, Takafumi ^a   Kugi, Mari ^d   Horiuchi, Seikoh ^c   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Prefectural Nichinan Hospital   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d NONE

Author keywords

ApoA I variant; Cholesterol efflux; HDL cholesterol; Kinetics

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MUTANT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RABBIT;

EID: 0033060423     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1447     Document Type: Article

References (63)

1. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
2. Brewer HB Jr, Fairwell T, LaRue A, Ronan R, Houser A, Bronzert TJ. The amino acid sequence of human apoA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun. 1978;80: 623-630.
3. Zannis VI, Karathanasis SK, Keutmann HT, Goldberger G, Breslow JL. Intracellular and extracellular processing of human apolipoprotein A-I: secreted apolipoprotein A-I isoprotein 2 is a propeptide. Proc Natl Acad Sci U S A. 1983;80:2574-2578.
4. Cheung P, Kao F-T, Law ML, Jones C, Puck TT, Chan L. Localization of the structural gene for human apolipoprotein A-I on the long arm of human chromosome 11. Proc Natl Acad Sci U S A. 1984;81:508-511.
5. Brouillette CG, Anantharamaiah GM. Structural model of human apolipoprotein A-I. Biochim Biophys Acta. 1995;1256:103-129.
6. Fielding PE, Kawano M, Catapano AL, Zoppo A, Marcovina S, Fielding CJ. Unique epitope of apolipoprotein A-I expressed in pre-β-1 high-density lipoprotein and its role in catalyzed efflux of cellular cholesterol. Biochemistry. 1994;33:6981-6985.
7. Jonas A, von Eckardstein A, Kézdy KE, Steinmetz A, Assmann G. Structural and functional properties of reconstituted high density lipoprotein discs prepared with six apolipoprotein A-I variants. J Lipid Res. 1991;32:97-106.
8. von Eckardstein A, Castro G, Wybranska I, Theret N, Duchateau P, Duverger N, Fruchart J-C, Ailhaud G, Assmann G. Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (apoA-I) variants with murine adipocytes and macrophages. J Biol Chem. 1993;268:2616-2622.
9. Sviridov D, Pyle L, Fidge N. Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles. Biochemistry. 1996;35:189-196.
10. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin-cholesterol acyltransferase reactivity. J Biol Chem. 1997;272: 7278-7284.
11. Allan CM, Fidge NH, Morrison JR, Kanellos J. Monoclonal antibodies to human apolipoprotein AI: probing the putative receptor binding domain of apolipoprotein AI. Biochem J. 1993;290:449-455.
12. Holvoet P, Zhao Z, Vonloo B, Vos R, Deridder E, Dhoest A, Taveirne J, Brouwers E, Demarsin E, Engelborghs Y, Rosseneu M, Collen D, Brasseur R. Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Biochemistry. 1995; 34:13334-13342.
13. Ji Y, Jonas A. Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J Biol Chem. 1995;270:11290-11297.
14. Schmidt HH-J, Remaley AT, Stonik JA, Ronan R, Wellmann A, Thomas F, Zech LA, Brewer JH, Hoeg JM. Carboxyl-terminal domain truncation alters apolipoprotein A-I in vivo catabolism. J Biol Chem. 1995;270: 5469-5475.
15. Minnich A, Collet X, Roghani A, Chadaras C, Hamiltom RL, Fielding CJ, Zannis VI. Site-directed mutagenesis and structure-function analysis of human apolipoprotein A-I: relation between lecithin-cholesterol acyltransferase activation and lipid binding. J Biol Chem. 1992;267: 16553-16560.
16. Takada Y, Sasaki J, Ogata S, Nakanishi T, Ikehara Y, Arakawa K. Isolation and characterization of apolipoprotein A-I Fukuoka (110Glu→Lys): a novel apolipoprotein variant. Biochim Biophys Acta. 1990;1043:169-176.
17. Takada Y, Sasaki J, Seki M, Ogata S, Teranishi Y, Arakawa K. Characterization of a new human apolipoprotein A-I Yame by direct sequencing of polymerase chain reaction-amplified DNA. J Lipid Res. 1991;32: 1275-1280.
18. Araki K, Sasaki J, Matsunaga A, Takada Y, Moriyama K, Hidaka K, Arakawa K. Characterization of two new human apolipoprotein A-I variants: apolipoprotein A-I Tsushima (Tip-108→Arg) and A-I Hita (Ala-95→Asp). Biochim Biophys Acta. 1994;1214:272-278.
19. Moriyama K, Sasaki J, Matsunaga A, Takada Y, Kagimoto M, Arakawa K. Identification of two apolipoprotein variants, A-I Karatsu (Tyr100→His) and A-I Kurume (162→Gln). Clin Genet. 1996;49: 79-84.
20. Moriyama K, Sasaki J, Matsunaga A, Arakawa K. Identification of two apolipoprotein variants. A-I (Asp 51→Val) and A-I Lys 107 deletion. J Atheroscler Thromb. 1996;3:12-16.
21. Huang W, Sasaki J, Matsunaga A, Nanamatsu K, Han H, Kugi M, Koga T, Yamaguchi K, Arakawa K. A novel homozygous missense mutation in apoA-I gene with apoA-I deficiency. Arterioscler Thromb Vasc Biol. 1998;18:389-396.
22. Deeb SS, Cheung MC, Peng R, Wolf AC, Stern R, Albers JJ, Knopp RH. A mutation in the human apolipoprotein A-I gene: dominant effect on the level and characteristics of plasma high density lipoproteins. J Biol Chem. 1991;266:13654-13660.
23. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L. Compound heterozygosity for a structural apolipoprotein A-I variant, apoA-I(L141R) Pisa, and an apolipoprotein A-I null allele in patients with absence in HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation. 1996;94:1622-1628.
24. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-I Milano apoprotein . isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest. 1980;66:901-907.
25. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein, apoA-I Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res. 1992;33:755-763.
26. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nsuyen O, Totty NF, Feest TG, Hsuan JJ, Pepys MB. Apolipoprotein A-I mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A. 992;89:7389-7393.
27. von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, Assmann G, Welp S, Roetrige A, Kock R. Apolipoprotein A-I variants: naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest. 1989;84:1722-1730.
28. Aiello DB, Zeller KI, Devlin CM, Friel GA, Miller M. Apolipoprotein A-I Zavalla (Leu 159→Pro): a novel mutation causing very low HDL cholesterol is associated with premature coronary artery heart disease. [Abstract]. Circulation. 1995;92(suppl I):I-494.
29. Moriyama K, Sasaki J, Takada Y, Matsunaga A, Fukui J, Albers JJ, Arakawa K. A cysteine-containing truncated apolipoprotein A-I associated with high density lipoprotcin deficiency. Arterioscler Thromb Vasc Biol. 1996;16:1416-1423.
30. Murakami M, Horiuchi S, Takata K, Morino Y. Distinction in the mode of receptor-mediated endocytosis between high density lipoprotein and acetylated high density lipoprotein: evidence for high density lipoprotein receptor-mediated cholesterol transfer. J Biochem. 1987;101:729-741.
31. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1882-1888.
32. Manabe M, Abe T, Nozawa M, Maki A, Hirata M, Itakura H. New substrate for determination of serum lecithin:cholesterol acyltransferase. J Lipid Res. 1987;28:1206-1215.
33. Paulweber B, Wiebusch H, Miesenboeck G, Funke H, Assmann G, Hoelzl B, Sippl MJ, Friedl W, Patsch JR, Sandhofer F. Molecular basis of lipoprotein lipase deficiency in two Austrian families with type I hyperlipoproteinemia. Atherosclerosis. 1991;86:239-250.
34. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665:408-419.
35. Karathanasis SK, Zannis V, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1983;80: 6147-6151.
36. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74:5463-5467.
37. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-2516.
38. Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985;82:488-492.
39. McFarlane AS. Efficient trace-labeling of protein with iodine. Nature. 1958;28:53-57.
40. Sasaki J, Cottam GL. Glycosylation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta. 1982;713:199-207.
41. Matthews CME. The theory of tracer experiments with iodine-131-labeled plasma proteins. Phys Med Biol. 1957;2:36-53.
42. Hakamata H, Miyazaki A, Sakai M, Suginohara Y, Sakamoto Y-I, Horiuchi S. Species difference in cholesteryl ester cycle and HDL-induced cholesterol efflux from macrophage foam cells. Arterioscler Thromb. 1994;14:1860-1865.
43. Sorci-Thomas M, Parks J, Kearns M, Pate G, Zhang C, Thomas M. High level secretion of wild-type and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. J Lipid Res. 1996;37: 673-683.
44. Pyle LE, Sawyer WH, Fujiwara Y, Mitchell A, Fidge NH. Structural and functional properties of full-length and truncated human proapolipoprotein AI expressed in Escherichia coli. Biochemistry. 1996;35: 12046-12052.
45. Sviridov D, Pyle LE, Fidge N. Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants. J Biol Chem. 1996;271: 33277-33283.
46. Oram J, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 1996;37:2473-2491.
47. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages: formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991;266:3080-3086.
48. Miccoli R, Zhu Y, Daum U, Wessling J, Huang Y, Navalesi R, Assmann G, von Eckardstein A. A natural apolipoprotein A-I variant, apoA-I(L141R) Pisa, interferes with the formation of α-high density lipoproteins (HDL) but not with the formation of pre-β1-HDL and influences efflux of cholesterol into plasma. J Lipid Res. 1997;38: 1242-1253.
49. Morrison J, Fidge NH, Tozuka M. Determination of the structural domain of apoAI recognized by high density lipoprotein receptors. J Biol Chem. 1991;266:18780-18785.
50. Dalton MB, Swaney JB. Structural and functional domains of apolipoprotein A-I within high density lipoproteins. J Biol Chem. 1993;268: 19274-19283.
51. Holvoet P, Zhao Z, Deridder E, Dhoest A, Collen D. Effect of deletion of the carboxyl-terminal domain of apoA-I or of its substitution with helices of apoA-II on in vitro and in vivo lipoprotein association. J Biol Chem. 1996;271:19395-19401.
52. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157:105-132.
53. Tilly-Kiesi M, Zhang Q, Ehnholm S, Kahri J, Lahdenpera S, Ehnholm C, Taskinen M-R. ApoA-I Helsinki (Lys107→0) associated with reduced HDL-cholesterol and LpA-I:A-II deficiency. Arterioscler Thromb Vasc Biol. 1995;15:1294-1306.
54. Bruckert E, von Eckardstein A, Funke H, Wiebusch H, Beucler I, Turpin G, Assmann G. The replacement of arginine by cysteine at residue 151 in apolipoproteinA-I produces a phenotype similar to that of apolipoproteinA-I Milano. Atherosclerosis. 1997;128:121-128.
55. Miettinen H, Gylling H, Miettinen T, Viikari J, Paulin L, Kontula K. Apolipoprotein A-I FIN dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Arterioscler Thromb Vasc Biol. 1997;17:83-90.
56. Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A. Heterozygosity for apolipoprotein A-I (R160L) Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. J Lipid Res. 1997;38:121-131.
57. Roma P, Gregg RE, Meng MS, Ronan R, Zech LA, Franceschini G, Sinori CR, Brewer HB Jr. In vivo metabolism of a mutant form of apolipoprotein A-I, apoA-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest. 1993;91:1445-1452.
58. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest. 1991;87: 371-376.
59. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knobe JD, Jacobs DR Jr, Bangdiwala S, Taylor HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
60. Karathanasis SK, Ferris E, Haddad IA. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987;84: 7198-7203.
61. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339-16342.
62. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, Yamakawa K, Yamanouchi Y, Tanaka I, Obara T, Hamaguchi H. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991;88:2793-2797.
63. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223-229.